Protalix holders back directors and stock plan
Protalix BioTherapeutics held its 2026 annual stockholder meeting, where investors approved all proposals presented.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Protalix BioTherapeutics held its 2026 annual stockholder meeting, where investors approved all proposals presented. Stockholders elected eight directors, with Eliot Richard Forster, Ph.D. receiving 32,871,013 votes for and 2,379,140 withheld, alongside 10,705,177 broker non-votes.
Investors approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 28,368,614 votes for and 6,683,937 against. They also approved an amended and restated 2006 Stock Incentive Plan, increasing the shares available under the plan from 17,475,171 to 20,975,171.
Stockholders ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 42,958,243 votes for, 2,001,734 against, and 995,352 abstentions.
8-K Event Classification
2 items: 5.07, 9.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Plan shares before amendment: 17,475,171 shares
Plan shares after amendment: 20,975,171 shares
Say-on-pay votes for: 28,368,614 votes
+4 more
7 metrics
Plan shares before amendment
17,475,171 shares
Common stock available under 2006 Stock Incentive Plan before increase
Plan shares after amendment
20,975,171 shares
Common stock available under amended 2006 Stock Incentive Plan
Say-on-pay votes for
28,368,614 votes
Advisory approval of named executive officer compensation
Say-on-pay votes against
6,683,937 votes
Advisory vote on executive compensation
Plan approval votes for
28,161,656 votes
Approval of amended and restated 2006 Stock Incentive Plan
Auditor ratification votes for
42,958,243 votes
Ratification of Kesselman & Kesselman as independent auditor for 2026
Votes for Eliot Richard Forster
32,871,013 votes
Director election at 2026 annual meeting
Key Terms
broker non-votes, non-binding, advisory basis, independent registered public accounting firm, Stock Incentive Plan, +1 more
5 terms
broker non-votes financial
"are the number of votes cast for or against or withheld, as applicable, the number of abstentions and the number of broker non-votes."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
non-binding, advisory basis regulatory
"approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"
A non-binding, advisory basis means a recommendation or decision that carries no legal force and does not obligate the parties to act; it’s similar to a friendly suggestion rather than a signed promise. For investors, this matters because such guidance can influence market expectations and management plans but offers no guarantee of follow-through, so investors should treat it as informative input rather than a firm commitment.
independent registered public accounting firm regulatory
"as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Stock Incentive Plan financial
"approved an Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan"
A stock incentive plan is a company program that gives employees or directors pieces of ownership or the right to buy shares over time, similar to receiving a bonus paid in company stock instead of cash. Investors pay attention because these plans align staff incentives with long‑term company performance but can also dilute existing shareholders and affect reported profits when grants are expensed, so they influence both ownership percentages and financial results.
Emerging growth company regulatory
"Emerging growth company ◻"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Protalix BioTherapeutics (PLX) stockholders approve at the 2026 annual meeting?
Stockholders approved all proposals, including electing eight directors, an advisory vote on executive compensation, an amended 2006 Stock Incentive Plan, and ratification of Kesselman & Kesselman as independent auditor for the fiscal year ending December 31, 2026.
How did Protalix (PLX) stockholders vote on executive compensation in 2026?
Stockholders approved, on a non-binding advisory basis, the compensation of Protalix’s named executive officers with 28,368,614 votes for, 6,683,937 against, 197,602 abstentions, and 10,705,177 broker non-votes recorded at the 2026 annual meeting.
Who was ratified as Protalix (PLX) independent auditor for 2026?
Kesselman & Kesselman, Certified Public Accountant (Isr.) and member of PricewaterhouseCoopers International Limited, was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 42,958,243 votes for and 2,001,734 against.
What were the vote results for director elections at Protalix (PLX) 2026 meeting?
Each of the eight director nominees was elected. For example, Eliot Richard Forster, Ph.D. received 32,871,013 votes for and 2,379,140 withheld, with 10,705,177 broker non-votes, indicating broad support across the director slate.
Did Protalix (PLX) stockholders approve the amended stock incentive plan?
Yes. The proposal to approve the amended and restated 2006 Stock Incentive Plan received 28,161,656 votes for, 6,974,902 against, 113,594 abstentions, and 10,705,177 broker non-votes at the 2026 annual stockholder meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
